Recall | Medicines | 27/07/2017

The marketing authorization holder has informed its supplied customers in a letter dated July 25, 2017, that a test result within the scope of a stability study showed a reduced active ingredient content. Therefore, the batch 559CG placed on the market in Austria, which is related to this stability study, is recalled from the market.

Name of the medicinal product Edronax 4 mg -Tabletten
Marketing authorisation number(s) 1-22230
Marketing authorisation holder Pfizer Corporation Austria GmbH
Batch number(s) 559CG
Classification of the recall2
BASG reference number INS - 640.001 - 2197

Further inquiry note